JPWO2021132550A1 - - Google Patents

Info

Publication number
JPWO2021132550A1
JPWO2021132550A1 JP2021567660A JP2021567660A JPWO2021132550A1 JP WO2021132550 A1 JPWO2021132550 A1 JP WO2021132550A1 JP 2021567660 A JP2021567660 A JP 2021567660A JP 2021567660 A JP2021567660 A JP 2021567660A JP WO2021132550 A1 JPWO2021132550 A1 JP WO2021132550A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021567660A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021132550A1 publication Critical patent/JPWO2021132550A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
JP2021567660A 2019-12-26 2020-12-25 Pending JPWO2021132550A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019236947 2019-12-26
PCT/JP2020/048667 WO2021132550A1 (ja) 2019-12-26 2020-12-25 術後補助療法剤

Publications (1)

Publication Number Publication Date
JPWO2021132550A1 true JPWO2021132550A1 (ja) 2021-07-01

Family

ID=76575547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567660A Pending JPWO2021132550A1 (ja) 2019-12-26 2020-12-25

Country Status (7)

Country Link
US (1) US20230055953A1 (ja)
EP (1) EP4082563A4 (ja)
JP (1) JPWO2021132550A1 (ja)
KR (1) KR20220120627A (ja)
AU (1) AU2020411439A1 (ja)
TW (1) TW202135854A (ja)
WO (1) WO2021132550A1 (ja)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
WO2015060235A1 (ja) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4138073B2 (ja) 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
US7041297B1 (en) 1998-06-25 2006-05-09 Sumitomo Pharmaceuticals Company Tumor antigen peptides originating in cyclophilin B
EP1116791B1 (en) 1998-08-28 2008-10-29 Kyogo Itoh Novel tumor antigen protein sart-3 and tumor antigen peptide thereof
CA2381348C (en) 1999-08-05 2009-10-06 Kyogo Itoh Lck-derived peptides activating ctls
AU2002227498A1 (en) 2000-07-31 2002-02-13 Kyogo Itoh Tumor antigen
JP4097178B2 (ja) 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
US7655751B2 (en) 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
WO2005116056A1 (ja) 2004-05-26 2005-12-08 Green Peptide Co., Ltd. 副甲状腺ホルモン関連タンパク質のhla-a24またはhla-a2結合ペプチド
JP2006188507A (ja) 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
JP5114403B2 (ja) 2006-07-11 2013-01-09 株式会社グリーンペプタイド Ｈｌａ−ａ３スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なｓａｒｔ３由来ペプチド
JP4972691B2 (ja) 2007-08-16 2012-07-11 株式会社グリーンペプタイド ＨＬＡ−Ａ３スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なＬｃｋ由来ペプチド
ES2874501T3 (es) 2013-10-18 2021-11-05 Taiho Pharmaceutical Co Ltd Animal no humano que expresa HLA de clase I

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
WO2015060235A1 (ja) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド

Also Published As

Publication number Publication date
AU2020411439A1 (en) 2022-08-04
WO2021132550A1 (ja) 2021-07-01
TW202135854A (zh) 2021-10-01
EP4082563A4 (en) 2024-02-28
EP4082563A1 (en) 2022-11-02
KR20220120627A (ko) 2022-08-30
US20230055953A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
BR112019017762A2 (ja)
BR112021017339A2 (ja)
BR112021013854A2 (ja)
BR112021018450A2 (ja)
BR112021017939A2 (ja)
BR112021017892A2 (ja)
BR112019016141A2 (ja)
BR112021017738A2 (ja)
BR112021017782A2 (ja)
BR112019016138A2 (ja)
BR112019016142A2 (ja)
BR112021018168A2 (ja)
BR112021017728A2 (ja)
AU2020104490A5 (ja)
BR112021008711A2 (ja)
BR112021017234A2 (ja)
BR112021017355A2 (ja)
BR112021017173A2 (ja)
BR112021018102A2 (ja)
BR112021017083A2 (ja)
BR112021017637A2 (ja)
BR112021018452A2 (ja)
BR112021012348A2 (ja)
BR112021018250A2 (ja)
BR112021018093A2 (ja)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240401